US-China Decoupling Gets On Biotech's Nerves
Wakeup Call For Companies, Experts Say
The Biden Administration’s latest Executive Order is aimed at shoring up investment in the US and securing supply chains for pharma and biotech products and is already impacting China's CDMO sector, but the long-term impact may be more nuanced, experts predict.
